New cancer drug RC88 tested in patients with advanced tumors
NCT ID NCT04175847
Summary
This study tested a new drug called RC88 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed early signs of helping to shrink tumors. The trial involved 198 participants with specific cancers, including mesothelioma and ovarian cancer, and looked at how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Drum Tower Hospital
Nanjing, Jiangsu, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.